Klaus Fuglsang Kofoed

Klaus Fuglsang Kofoed

Auto-generated profile, based on publicly available information

Klaus Fuglsang Kofoed

Department of Cardiology, the Heart Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
RMRaj R. Makkar
Raj R. Makkar
GFGregory Fontana
Gregory Fontana
HJHasan Jilaihawi
Hasan Jilaihawi
TCTarun Chakravarty
Tarun Chakravarty
KKKlaus F. Kofoed
Klaus F. Kofoed
LSLars Søndergaard
Lars Søndergaard
A finding of reduced aortic-valve leaflet motion was noted on computed tomography (CT) in a patient who had a stroke after transcatheter aortic-valve replacement (TAVR) during an ongoing clinical trial. This finding raised a concern about possible subclinical leaflet thrombosis and prompted further investigation. We analyzed data obtained from 55 patients in a clinical trial of TAVR and from two single-center registries that included 132 patients who were undergoing either TAVR or surgical aortic-valve bioprosthesis implantation. We obtained four-dimensional, volume-rendered CT scans along with data on anticoagulation and clinical outcomes (including strokes and transient ischemic attacks [TIAs]). Reduced leaflet motion was noted on CT in 22 of 55 patients (40%) in the clinical trial and in 17 of 132 patients (13%) in the two registries. Reduced leaflet motion was detected among patients with multiple bioprosthesis types, including transcatheter and surgical bioprostheses. Therapeutic anticoagulation with warfarin, as compared with dual antiplatelet therapy, was associated with a decreased incidence of reduced leaflet motion (0% and 55%, respectively, P=0.01 in the clinical trial; and 0% and 29%, respectively, P=0.04 in the pooled registries). In patients who were reevaluated with follow-up CT, restoration of leaflet motion was noted in all 11 patients who were receiving anticoagulation and in 1 of 10 patients who were not receiving anticoagulation (P<0.001). There was no significant difference in the incidence of stroke or TIA between patients with reduced leaflet motion and those with normal leaflet motion in the clinical trial (2 of 22 patients and 0 of 33 patients, respectively; P=0.16), although in the pooled registries, a significant difference was detected (3 of 17 patients and 1 of 115 patients, respectively; P=0.007). Reduced aortic-valve leaflet motion was shown in patients with bioprosthetic aortic valves. The condition resolved with therapeutic anticoagulation. The effect of this finding on clinical outcomes including stroke needs further investigation. (Funded by St. Jude Medical and Cedars–Sinai Heart Institute; Portico-IDE ClinicalTrials.gov number, NCT02000115; SAVORY registry, NCT02426307; and RESOLVE registry, NCT02318342.)

1 June 2017 in The Lancet
Verified
Journal Article
Closed access
TCTarun Chakravarty
Tarun Chakravarty
LSLars Søndergaard
Lars Søndergaard
JFJohn Friedman
John Friedman
OBOle De Backer
Ole De Backer
DBDaniel Berman
Daniel Berman
HIHelle Klingenberg Iversen
Helle Klingenberg Iversen

19 November 2013 in European Heart Journal
Verified
Journal Article
Open access
PDF file
CRCarlos E. Rochitte
Carlos E. Rochitte
RGRichard T. George
Richard T. George
MCMarcus Y. Chen
Marcus Y. Chen
AAArmin Arbab-Zadeh
Armin Arbab-Zadeh
MDMarc Dewey
Marc Dewey
JLJoao A. C. Lima
Joao A. C. Lima
Aims: To evaluate the diagnostic power of integrating the results of computed tomography angiography (CTA) and CT myocardial perfusion (CTP) to identify coronary artery disease (CAD) defined as a flow limiting coronary artery stenosis causing a perfusion defect by single photon emission computed tomography (SPECT).Methods and results: We conducted a multicentre study to evaluate the accuracy of integrated CTA–CTP for the identification of patients with flow-limiting CAD defined by ≥50% stenosis by invasive coronary angiography (ICA) with a corresponding perfusion deficit on stress single photon emission computed tomography (SPECT/MPI). Sixteen centres enroled 381 patients who underwent combined CTA–CTP and SPECT/MPI prior to conventional coronary angiography. All four image modalities were analysed in blinded independent core laboratories. The prevalence of obstructive CAD defined by combined ICA–SPECT/MPI and ICA alone was 38 and 59%, respectively. The patient-based diagnostic accuracy defined by the area under the receiver operating characteristic curve (AUC) of integrated CTA–CTP for detecting or excluding flow-limiting CAD was 0.87 [95% confidence interval (CI): 0.84–0.91]. In patients without prior myocardial infarction, the AUC was 0.90 (95% CI: 0.87–0.94) and in patients without prior CAD the AUC for combined CTA–CTP was 0.93 (95% CI: 0.89–0.97). For the combination of a CTA stenosis ≥50% stenosis and a CTP perfusion deficit, the sensitivity, specificity, positive predictive, and negative predicative values (95% CI) were 80% (72–86), 74% (68–80), 65% (58–72), and 86% (80–90), respectively. For flow-limiting disease defined by ICA-SPECT/MPI, the accuracy of CTA was significantly increased by the addition of CTP at both the patient and vessel levels.Conclusions: The combination of CTA and perfusion correctly identifies patients with flow limiting CAD defined as ≥50 stenosis by ICA causing a perfusion defect by SPECT/MPI.

27 January 2012 in Thorax
Verified
Journal Article
Open access
PDF file
ZSZaigham Saghir
Zaigham Saghir
ADAsger Dirksen
Asger Dirksen
HAHaseem Ashraf
Haseem Ashraf
KBKaren Skjøldstrup Bach
Karen Skjøldstrup Bach
JBJohn Brodersen
John Brodersen
JPJesper Holst Pedersen
Jesper Holst Pedersen
Background The effects of low-dose CT screening on disease stage shift, mortality and overdiagnosis are unclear. Lung cancer findings and mortality rates are reported at the end of screening in the Danish Lung Cancer Screening Trial. Methods 4104 men and women, healthy heavy smokers/former smokers were randomised to five annual low-dose CT screenings or no screening. Two experienced chest radiologists read all CT scans and registered the location, size and morphology of nodules. Nodules between 5 and 15 mm without benign characteristics were rescanned after 3 months. Growing nodules (>25% volume increase and/or volume doubling time15 mm were referred for diagnostic workup. In the control group, lung cancers were diagnosed and treated outside the study by the usual clinical practice. Results Participation rates were high in both groups (screening: 95.5%; control: 93.0%; p<0.001). Lung cancer detection rate was 0.83% at baseline and mean annual detection rate was 0.67% at incidence rounds (p=0.535). More lung cancers were diagnosed in the screening group (69 vs 24, p<0.001), and more were low stage (48 vs 21 stage I–IIB non-small cell lung cancer (NSCLC) and limited stage small cell lung cancer (SCLC), p=0.002), whereas frequencies of high-stage lung cancer were the same (21 vs 16 stage IIIA–IV NSCLC and extensive stage SCLC, p=0.509). At the end of screening, 61 patients died in the screening group and 42 in the control group (p=0.059). 15 and 11 died of lung cancer, respectively (p=0.428). Conclusion CT screening for lung cancer brings forward early disease, and at this point no stage shift or reduction in mortality was observed. More lung cancers were diagnosed in the screening group, indicating some degree of overdiagnosis and need for longer follow-up.

29 April 2015 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
AMAnders Bruun Mathiasen
Anders Bruun Mathiasen
AQAbbas Ali Qayyum
Abbas Ali Qayyum
EJErik Jørgensen
Erik Jørgensen
SHSteffen Helqvist
Steffen Helqvist
AFAnne Fischer-Nielsen
Anne Fischer-Nielsen
JKJens Kastrup
Jens Kastrup
Aims Regenerative treatment with mesenchymal stromal cells (MSCs) has been promising in patients with ischaemic heart failure but needs confirmation in larger randomized trials. We aimed to study effects of intra-myocardial autologous bone marrow-derived MSC treatment in patients with severe ischaemic heart failure. Methods and results The MSC-HF trial is a randomized, double-blind, placebo-controlled trial. Patients were randomized 2 : 1 to intra-myocardial injections of MSC or placebo, respectively. The primary endpoint was change in left ventricular end-systolic volume (LVESV), measured by magnetic resonance imaging or computed tomography at 6 months follow-up. Sixty patients aged 30–80 years with severe ischaemic heart failure, New York Heart Association (NYHA) classes II–III, left ventricular ejection fraction (LVEF) <45% and no further treatment options were randomized. Fifty-five patients completed the 6-month follow-up (37 MSCs vs. 18 placebo). At 6 months, LVESV was reduced in the MSC group: −7.6 (95% CI −11.8 to −3.4) mL ( P = 0.001), and increased in the placebo group: 5.4 (95% CI −0.4 to 11.2) mL ( P = 0.07). The difference between groups was 13.0 (95% CI 5.9–20.1) mL ( P = 0.001). Compared with placebo, there were also significant improvements in LVEF of 6.2% ( P <0.0001), stroke volume of 18.4 mL ( P < 0.0001), and myocardial mass of 5.7 g ( P = 0.001). No differences were found in NYHA class, 6-min walking test and Kansas City cardiomyopathy questionnaire. No side effects were identified. Conclusion Intra-myocardial injections of autologous culture expanded MSCs were safe and improved myocardial function in patients with severe ischaemic heart failure. Study registration number NCT00644410 (ClinicalTrials.gov).

9 January 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
OBOle De Backer
Ole De Backer
GDGeorge D. Dangas
George D. Dangas
HJHasan Jilaihawi
Hasan Jilaihawi
JLJonathon A. Leipsic
Jonathon A. Leipsic
CTChristian J. Terkelsen
Christian J. Terkelsen
LSLars Sondergaard
Lars Sondergaard
Subclinical leaflet thickening and reduced leaflet motion of bioprosthetic aortic valves have been documented by four-dimensional computed tomography (CT). Whether anticoagulation can reduce these phenomena after transcatheter aortic-valve replacement (TAVR) is not known.